Vaxcyte (PCVX) Income towards Parent Company (2019 - 2026)

Vaxcyte (PCVX) has 8 years of Income towards Parent Company data on file, last reported at -$322.9 million in Q1 2026.

• On a quarterly basis, Income towards Parent Company fell 113.95% year-over-year to -$322.9 million in Q1 2026; TTM through Mar 2026 was -$1.3 billion, a 160.47% decrease from a year earlier, with the FY2025 full-year figure at -$1.4 billion, down 60.03% from the prior year.
• Income towards Parent Company for Q1 2026 stood at -$322.9 million, up from -$378.2 million in the prior quarter.
• Over the last five years, Income towards Parent Company for PCVX reached as high as -$79.9 million in Q4 2022 and fell as low as -$455.9 million in Q1 2024.
• Historically, Income towards Parent Company has averaged -$224.2 million across 5 years, with a median of -$179.1 million in 2023.
• Across the five-year window, Income towards Parent Company tumbled 380.33% in 2022 and soared 66.89% in 2025, its largest moves.
• Year by year, Income towards Parent Company stood at -$79.9 million in 2022, then sank by 124.05% to -$179.1 million in 2023, then jumped by 34.51% to -$117.3 million in 2024, then sank by 222.39% to -$378.2 million in 2025, then grew by 14.61% to -$322.9 million in 2026.
• Per Business Quant data, the three most recent Income towards Parent Company figures were -$322.9 million in Q1 2026, -$378.2 million in Q4 2025, and -$331.1 million in Q3 2025.